肝硬化与骨代谢障碍

doi:10.3969/j.issn.1672-5069.2017.04.002

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (4): 388-390.doi: 10.3969/j.issn.1672-5069.2017.04.002

肝硬化与骨代谢障碍

熊吉, 文良志, 孙文静, 陈东风

400042 重庆市第三军医大学大坪医院野战外科研究所消化内科

收稿日期:2017-05-04 出版日期:2017-07-10 发布日期:2017-07-07
通讯作者: 陈东风,E-mail:chendf1981@126.com
作者简介:熊吉,女,35岁,医学博士,主治医师。主要研究方向：慢性肝病防治研究。E-mail:xjazh@21cn.com

Disorders of bone metabolism in patients with chronic liver disease

Xiong Ji, Wen Liangzhi, Sun Wenjing, et al.

Department of Gastroenterology,Institute of Field Surgery Research,Daping Hospital,Third Military Medical University,Chongqing 400042, China

Received:2017-05-04 Online:2017-07-10 Published:2017-07-07

摘要/Abstract

关键词: 肝硬化, 骨代谢, 肝性骨病

Key words: Liver cirrhosis, Bone metabolism, Hepatic bone diseases

熊吉, 文良志, 孙文静, 陈东风. 肝硬化与骨代谢障碍[J]. 实用肝脏病杂志, 2017, 20(4): 388-390.

Xiong Ji, Wen Liangzhi, Sun Wenjing, et al.. Disorders of bone metabolism in patients with chronic liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 388-390.

[1] Gasser RW. Cholestasis and metabolic bone disease-a clinical review. Wien Med Wochenschr,2008,158（19-20）:553-557.
[2] Raszeja-Wyszomirska J,Miazgowski T. Osteoporosis in primary biliary cirrhosis of the liver. Prz Gastroenterol,2014,9（2）: 82-87.
[3] Gonzalez-Calvin JL,Gallego-Rojo F,Fernandez-Perez R,et al. Osteoporosis,mineral metabolism,and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab,2004,89（9）:4325-4330.
[4] Goubraim R,Kabbaj N,Salihoun M,et al. Metabolic bone disease in viral cirrhosis:A prospective study. ISRN Hepatol,2013,2013: 276563.
[5] Wariaghli G, Allali F, El Maghraoui A, et al. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol, 2010,22（12）: 1397-1401.
[6] Guichelaar MM,Malinchoc M,Sibonga J,et al. Bone metabolism in advanced cholestatic liver disease:analysis by bone histomorphometry. Hepatology, 2002,36（4 Pt 1）: 895-903.
[7] Miroliaee A,Nasiri-Toosi M,Khalilzadeh O,et al. Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease:a cross-sectional study. Hepatol Int,2010,4（3）:634-640.
[8] Luxon BA. Bone disorders in chronic liver diseases. Curr Gastroenterol Rep,2011,13（1）:40-48.
[9] Nakchbandi IA. Osteoporosis and fractures in liver disease: relevance,pathogenesis and therapeutic implications. World J Gastroenterol,2014,20（28）:9427-9438.
[10] Strandberg L,Lorentzon M,Hellqvist A,et al. Interleukin-1 system gene polymorphisms are associated with fat mass in young men. J Clin Endocrinol Metab,2006,91（7）:2749-2754.
[11] Ye XL,Lu CF. Association of polymorphisms in the leptin and leptin receptor genes with inflammatory mediators in patients with osteoporosis. Endocrine,2013,44（2）:481-488.
[12] Vermeer C. Vitamin K:the effect on health beyond coagulation -an overview. Food Nutr Res,2012,56:321-325..
[13] Garcia-Valdecasas-Campelo E,Gonzalez-Reimers E,Santolaria-
Fernandez F,et al. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol,2006,41（3）: 261-266.
[14] Walsh MC,Choi Y. Biology of the RANKL-RANK-OPG system in immunity,bone,and beyond. Front Immunol,2014,5:511.
[15] Lleo A,Bian Z,Zhang H,et al. Quantitation of the Rank-Rankl axis in primary biliary cholangitis. PLoS One,2016,11（9）:e0159612.
[16] Wu Q,Zhou X,Huang D,et al. IL-6 Enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro. Cell Physiol Biochem,2017,41（4）: 1360-1369.
[17] 高学松,段雪飞. 肝硬化合并肝性骨病的研究进展. 中国肝脏病杂志,2015,7（4）: 14-18.
[18] Oei L,Koromani F,Rivadeneira F,et al. Quantitative imaging methods in osteoporosis. Quant Imaging Med Surg,2016,6（6）: 680-698.
[19] Engelke K,Libanati C,Liu Y,et al. Quantitative computed tomography （QCT） of the forearm using general purpose spiral whole-body CT scanners:accuracy,precision and comparison with dual-energy X-ray absorptiometry （DXA）. Bone,2009,45（1）:110-118.
[20] 李康军,王小英, 任志. 肝硬化患者腰椎骨密度CT定量评价. 医学信息,2011,9: 4317.
[21] Santos LA,Romeiro FG. Diagnosis and management of cirrhosis-related osteoporosis. 2016,2016: 1423462.
[22] Levy C,Harnois DM, Angulo P,et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int,2005,25（1）:117-121.

肝硬化与骨代谢障碍

Disorders of bone metabolism in patients with chronic liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[3]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[4]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[5]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[6]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[7]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[8]	王月圆, 王燕, 张丹丹. 奥曲肽辅助特利加压素治疗失代偿期肝硬化并发肝肾综合征患者疗效分析*[J]. 实用肝脏病杂志, 2019, 22(5): 684-687.
[9]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[10]	丹珠永吉, 刘芝兰, 禄艳艳, 蒋汉梅. 内镜下序贯套扎和硬化剂治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效及对血流动力学的影响对比研究*[J]. 实用肝脏病杂志, 2019, 22(5): 692-695.
[11]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[12]	赵芳芳, 翟永贞, 冯国和. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(5): 700-703.
[13]	陈山, 庄华帅, 邢诒喜, 吴直佳. 美罗培南治疗肝硬化并发上消化道出血患者对感染预防和再出血的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 704-707.
[14]	徐祺林, 郝少欢, 冉博. 肝硬化脾切除术后门静脉系统血栓形成的危险因素分析*[J]. 实用肝脏病杂志, 2019, 22(5): 708-711.
[15]	金良红, 李兴杰, 关红博, 麻少辉. 双能量CT碘定量结合动态对比增强MRI评估肝硬化患者肝脏血流动力学和肝功能临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 712-715.